Genetics of Renal Cell Carcinoma

Ln, Daniel; Wm, Linehan

doi:10.1007/978-3-319-92309-3_3

Cited by 4 publications

(3 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biopsy of lesions suspicious of metastasis is also recommended even with known primary tumour [4] to avoid pitfalls, and therefore biopsies also were done in the cases presented herein. Renal clear cell cancer is typically radioresistant and surgery is advised for solitary metachronous R0-resectable lesions [5][6][7][8][9][10][11].…”

Section: Case Reports In Oncologymentioning

confidence: 99%

Resection of Renal Cell and Prostate Carcinoma Sternum Metastases with Long-Term Follow-Up: A Report of 2 Cases

Berdat,

Vogt,

Schai

et al. 2024

Case Rep Oncol

View full text Add to dashboard Cite

Introduction: Rarely solitary sternum metastases are addressed by resection. Two additional cases are presented as they are interesting because of their long-term follow-up. Case Presentation: Case 1: A renal cell carcinoma was treated by transabdominal nephrectomy at age 64. Right iliac bone and sternum metastases were diagnosed 7 months later and treated by internal hemipelvectomy followed by sternum metastasectomy 6 weeks after the internal hemipelvectomy. At 12-year follow-up, the patient appears disease free. Case 2: Prostate cancer was treated by prostatectomy at age 67. A subsequent solitary sternum metastasis was resected 10 years later for persistent PSA-activity despite repeated radiotherapy. The patient remains asymptomatic for 3 years now. Conclusion: Resection of sternum metastases may have curative potential and should be considered in tumours known to be rather resistant to chemo- and/or radiotherapy.

show abstract

Section: Case Reports In Oncologymentioning

confidence: 99%

Resection of Renal Cell and Prostate Carcinoma Sternum Metastases with Long-Term Follow-Up: A Report of 2 Cases

Berdat,

Vogt,

Schai

et al. 2024

Case Rep Oncol

View full text Add to dashboard Cite

show abstract

“…Interestingly, the advances in survival were seen exclusively in patients with advanced RCC (stage III and IV), while survival rates for lower stages have essentially leveled off at the time of publishing in 2015. This last point suggests that additional gains in survival are largely based on improvements in treatment options as new systemic therapies were approved for advanced kidney cancer [5][6][7], while treatment of primary tumors with nephrectomy is still utilized as the mainstay therapy in low-stage kidney cancer [8]. Thus, as survivability and treatment options for the localized disease have plateaued, advancements in imaging to better predict histological subtypes and grades may further contribute to improved survivability in the coming years.…”

Section: Introductionmentioning

confidence: 99%

MR Virtual Biopsy of Solid Renal Masses: An Algorithmic Approach

Chartier

Arif-Tiwari

2023

Cancers

View full text Add to dashboard Cite

Between 1983 and 2002, the incidence of solid renal tumors increased from 7.1 to 10.8 cases per 100,000. This is in large part due to the increase in the volume of ultrasound and cross-sectional imaging, although a majority of solid renal tumors are still found incidentally. Ultrasound and computed tomography (CT) have been the mainstay of renal mass screening and diagnosis but recent advances in magnetic resonance (MR) technology have made this the optimal choice when diagnosing and staging renal tumors. Our purpose in writing this review is to survey the modern MR imaging approach to benign and malignant solid renal tumors, consolidate the various imaging findings into an easy-to-read reference, and provide an imaging-based, algorithmic approach to renal mass characterization for clinicians. MR is at the forefront of renal mass characterization, surpassing ultrasound and CT in its ability to describe multiple tissue parameters and predict tumor biology. Cutting-edge MR protocols and the integration of diagnostic algorithms can improve patient outcomes, allowing the imager to narrow the differential and better guide oncologic and surgical management.

show abstract

“… 25 Historical trials utilizing systemic therapy with VEGF-TKI and interleukin-2 included patients who have underwent prior nephrectomy rates from 67% to 100%. 26 However, more contemporary front-line therapies with IO/IO or IO/VEGF-TKI treatment often includes patients who have not undergone nephrectomy with 16.6% of the population in Keynote-426, 27 with the primary tumor in place, and 20.2% in the JAVELIN Renal 101, 28 22% in the CheckMate 214, 29 25.1% in the CLEAR trial, 30 30.1% in the CheckMate 9ER, 31 and 36% in the COSMIC-313 trial, 32 the latter of which has the most number of patients who have primary renal tumor in place and have not undergone nephrectomy. Questions regarding safety and efficacy also abound with the use of upfront nephrectomy.…”

mentioning

confidence: 99%